- Home
- IMCR vs PLGO Comparison
IMCR vs PLGO Comparison
Compare IMCR & PLGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IMCR | PLGO |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United Kingdom | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2016 | 2015 |
Fundamental Metrics
Financial Performance| Metric | IMCR | PLGO |
|---|---|---|
| Price | $37.40 | $24.16 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $66.33 | N/A |
| AVG Volume (30 Days) | 406.6K | ★ 487.2K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $8.21 | N/A |
| P/E Ratio | $159.17 | ★ N/A |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $20.85 |
| 52 Week High | $40.71 | $26.34 |
Technical Indicators
Market Signals| Indicator | IMCR | PLGO |
|---|---|---|
| Relative Strength Index (RSI) | 65.81 | 51.04 |
| Support Level | $35.46 | $24.19 |
| Resistance Level | $37.25 | $26.06 |
| Average True Range (ATR) | 1.27 | 0.79 |
| MACD | 0.19 | -0.03 |
| Stochastic Oscillator | 90.54 | 67.17 |
Price Performance
Historical ComparisonAbout IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PLGO Pelagos Insurance Capital Limited Common Shares
Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.